Cannabis Clinical Trial
Official title:
The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A
The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of a novel hemp-derived oral cannabinoid product, at various doses, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design. Drug administration will be double blind (the participant and research staff will be unaware of the dose administered). Upon enrollment, participants will complete 4 dosing conditions (placebo, 1 mg/kg, 2 mg/kg, 4 mg/kg of cannabinoids). Each condition will consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute pharmacodynamic and pharmacokinetic (PK) drug effects. Biological specimens (blood and urine) will be obtained throughout these 8 hours to characterize the pharmacokinetics of CBD, CBD-A, delta-9-Tetrahydrocannabinol (THC), and THC-A, as well as other relevant cannabinoids and metabolites. Pharmacodynamic assessments including subjective drug effects, cognitive performance testing, and vital signs will also be collected for 8 hours post-drug administration. For each of the two days after each experimental session, participants will be asked to return to the lab for brief visits (~20 min) to provide additional biospecimens (~24 and ~48 hrs after dosing) to allow for further PK analysis. These procedures will be completed 4 separate times by each participant (sessions will be separated by at least 1 week to allow for sufficient drug washout between doses). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
| Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
| Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
| Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
| Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
| Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
| Completed |
NCT04124432 -
Behavioral Pharmacology of Cannabis and Nicotine
|
Phase 1 | |
| Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
| Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
| Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
| Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
| Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
| Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
| Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
| Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
| Completed |
NCT02567344 -
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
|
N/A | |
| Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 |